EQRx Appoints Carlos Garcia-Echeverria, Ph.D., as Chief of Rx Creation
Key leadership appointment underscores EQRx’s commitment to substantially accelerate creation of novel medicines
CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, today announced the appointment of Carlos Garcia-Echeverria, Ph.D., as chief of Rx creation. In this role, Carlos will be responsible for leading EQRx’s drug creation and early-stage research and development functions to continue to build a robust and sustainable pipeline of novel medicines.
“Carlos brings deep expertise across platforms, modalities and therapeutic categories, as well as his grounding in cutting-edge digital technologies, which further bolsters EQRx’s capability to realize the incredible potential of what’s possible through drug engineering,” said Melanie Nallicheri, president and chief operating officer of EQRx. “Carlos’ scientific aptitude will be invaluable as we augment our existing portfolio with an extensive pipeline of impactful drug candidates across disease areas to lead the way in the future of affordable medicines, particularly in light of our recently announced R&D collaboration with AI-based drug discovery leader Exscientia and others in the offing.”
Dr. Carlos Garcia-Echeverria joins EQRx from Sanofi, most recently serving as the chief operating officer of research and global head of research platforms, where he was responsible for overseeing the establishment and execution of the Sanofi research strategy. Before joining Sanofi in 2010, Carlos held several positions of increasing responsibility at Novartis, including executive director, oncology drug discovery head, where he was responsible for managing multiple late-stage drug discovery cancer programs. Carlos is an inventor on 45 patents and has published more than 190 peer-reviewed articles, book chapters and review papers. He received his Ph.D. in organic chemistry from the University of Barcelona.
“This is a unique opportunity to build out an early-stage portfolio at unparalleled scale with a truly noble mission for equitable patient access,” said Dr. Carlos Garcia-Echeverria. “I look forward to building out the Company’s world-class early-stage R&D functions. I believe this is the right time for a holistic, disruptive change in the pharmaceutical industry and to bring much needed effective therapies to patients sooner and at significantly lower overall cost.”
EQRx is committed to catalyzing a market-based solution to one of society’s biggest healthcare challenges by developing important new medicines and offering them at lower prices. Through strategic partnerships with stakeholders from across the healthcare system and cutting-edge science and technology, the Company aims to provide high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. EQRx is a purpose-built disruptor at scale, remaking medicine to bend the cost curve in drug pricing. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx, Inc.